StockDuty ← Dashboard Sep 26, 2026 02:33 AM ET
SignalFDA/Bio

Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences to present topline Phase 3 DAYBREAK results for Zenkuda and KSI-501 in wet AMD.

What changed
Kodiak Sciences to present topline Phase 3 DAYBREAK results for Zenkuda and KSI-501 in wet AMD.
Why it matters
Kodiak Sciences to present topline Phase 3 DAYBREAK results for Zenkuda and KSI-501 in wet AMD. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →